COSCIENS Biopharma Inc. (NASDAQ:CSCI – Get Free Report) shares shot up 2.8% during mid-day trading on Tuesday . The stock traded as high as $3.11 and last traded at $2.90. 7,910 shares traded hands during trading, a decline of 44% from the average session volume of 14,119 shares. The stock had previously closed at $2.82.
COSCIENS Biopharma Stock Performance
The firm has a market cap of $10.23 million, a price-to-earnings ratio of -0.23 and a beta of 1.47. The stock’s fifty day moving average is $2.89 and its two-hundred day moving average is $3.16.
About COSCIENS Biopharma
COSCIENS Biopharma Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Articles
- Five stocks we like better than COSCIENS Biopharma
- What is the FTSE 100 index?
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- Trading Stocks: RSI and Why it’s Useful
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- Canada Bond Market Holiday: How to Invest and Trade
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Receive News & Ratings for COSCIENS Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COSCIENS Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
